key: cord-0716710-svl40q8w
authors: Ngo, Andy; Masel, Debra; Cahill, Christine; Blumberg, Neil; Refaai, Majed
title: Blood Banking and Transfusion Medicine Challenges During the COVID-19 Pandemic
date: 2020-08-08
journal: Clin Lab Med
DOI: 10.1016/j.cll.2020.08.013
sha: b91d2eee9997acd435403fb3695ab8580e29790f
doc_id: 716710
cord_uid: svl40q8w

SARS-CoV-2 (also known as COVID-19) has been unprecedented challenge in many parts of the medical field with blood banking being no exception. COVID-19 has had a distinctly negative effect on our blood collection nationwide forcing blood banks, blood centers, and the U.S. government to adopt new policies to adapt to a decreased blood supply as well as to protect our donors from COVID-19. These policies can be seen distinctly in patient blood management and blood bank operations. We are also faced with developing policies and procedures for a non-traditional therapy, convalescent plasma; its efficacy and safety is still not completely elucidated as of yet.

Within three months of the first diagnosed case, the outbreak of acute respiratory disease caused by the novel coronavirus (SARS-CoV-2), also known as COVID-19, rapidly grew into a global pandemic. The eruption of this virus, reportedly, may have been linked to a seafood and wildlife market in Wuhan, Hubei Province, China [1] [2] . Person to person spread is thought to occur via respiratory droplet contact (≤6 feet), skin contacts and even the transmission through air while speaking. Despite the extraordinary universal attempts to limit the spread of this virus, new cases are diagnosed on a daily basis throughout the world and have dramatically impacted, among other healthcare disciplines, the blood bank and transfusion medicine. Due to the growing prevalence and highly infectious nature of COVID-19, new policies and guidelines have started to develop in transfusion medicine practices. In this chapter we will address the myriad of ways that COVID-19 has impacted blood banking and transfusion medicine including the safety of both blood donors and blood product recipients, the management and distribution of blood products during a pandemic, and the use of blood-product derived therapeutics.

Common symptoms of COVID-19 infection, which typically appear within 2 to 14 days after exposure, include fever, sore throat, cough, shortness of breath, chills, muscle pain, headache, and sensory changes such as loss of smell or taste. Nausea, vomiting, diarrhea, skin rash, delirium, and dizziness have also been reported [3, 4] . In advanced cases, mild to severe lower respiratory tract infection can be seen and may progress to critical status, as a result of the cytokine storm, requiring intubation and mechanical ventilation. Acute respiratory failure and a widespread thromboembolic disease are also common in these critical cases [5, 6] . However, conservative estimates of 30% to as high as 96% of infected individuals may manifest mild to no symptoms posing huge challenges in containing this pandemic crisis and protecting blood donors [7] .

In one of the earlier studies of COVID-19 patients, Guan et al. [8] reported that in addition to the usual viral route of respiratory droplets, the virus could be transmitted by saliva, urine and stool [9] . Extracted data of 1,099 patients with laboratory-confirmed COVID-19related acute respiratory distress syndrome (ARDS) showed a predominant male gender (58%), median age of 47 years with most common symptoms of fever (88%) and cough (68%). The median incubation period was found to be 3 days with a range of 0 to 24 days. Only 1.2% of patients reported to have a direct contact with wildlife and 31% had been to Wuhan city while the majority (72%) had contact with people from Wuhan city. At time of admission, groundglass opacity was the typical (56.4%) radiological finding on chest-computed tomography (CT scan). Interestingly, a significant number of severe cases were diagnosed by clinical symptoms and real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) with normal J o u r n a l P r e -p r o o f radiological findings. Multivariate analysis revealed that severe pneumonia was an independent factor associated with either ICU admission, mechanical ventilation, or death (hazards ratio, 9. 80; 95% confidence interval, 4.06 to 23.67) [8] .

Ideally, testing every blood donor for COVID-19 would be the best practice; however, at least for the time being, this task cannot realistically be accomplished. To date, seven recognized types of coronavirus strains have been identified which can infect humans, include Alpha coronavirus (229E and NL63) and Beta coronavirus (OC43 and HKU1). The rare but more severe types are called MERS-CoV, which leads to Middle East Respiratory Syndrome (MERS), and SARS-CoV, responsible for Severe Acute Respiratory Syndrome (SARS) endemic [10] .

Laboratory confirmation of COVID-19 infection is based on detection of unique sequences of viral RNA by RT-PCR. Sputum samples provide better detection than throat samples, while lower respiratory tract samples are superior to those from the upper respiratory tract [11] . The presence of SARS-CoV-2 RNA in the blood is a marker of severe illness based on 113 studies. [12] . Additional laboratory findings in COVID-19 infection include lymphopenia (83%), neutrophilia, and elevated levels of serum alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, CRP, ferritin, and D-dimer [13] . Substantial increase in CRP, ferritin, and D-dimer levels were found to be associated with severe infection [14] . In addition, significant association has been recognized between lymphopenia and high levels o f D-dimer with mortality [15] [16] .

J o u r n a l P r e -p r o o f Bilateral air-space consolidation is typically seen on CXR; however, findings may be unremarkable early in the disease. Chest CT images usually demonstrate bilateral, peripheral ground glass opacities, which is non-specific to COVID-19 infection.

An effective COVID-19 vaccine would be the ultimate solution for all of the concerns surrounding blood bank industry. However, currently there is no vaccine available to protect against SARS-CoV-2. Likewise, no prophylactic therapy has yet been proven to be effective in patients who have been exposed to SARS-CoV-2 nor a clearly successful treatment for those who develop the infection [17] . Patients that are confirmed positive for COVID-19 and present with mild symptoms are usually managed by self-isolation at home for up to 14 days which is also the minimal deferral period recommended by many blood centers [7] [8] [9] [10] . In advanced cases, Early detection, triage, and isolation of potentially infectious patients are also important considerations. A combination of these measures is the basis of current blood donation protocols which will hopefully protect and maintain our blood supply.

There are multiple Federal Drug Administration (FDA) criteria a blood donor must meet before donating blood products. These parameters range from physical requirements such as age, weight, temperature, blood pressure, and pulse to a background check of the donors sexual, medical, and travel history. Any discrepancies or issues that arise during the interview process and the physical examination could temporarily or permanently defer the donor from the blood donation system [18] .

Following the start of the COVID-19 outbreak in the U.S, additional screening questions and requirements were implemented. Although not standardized across all blood collection organizations, the American Red Cross implemented new deferral policies in February 2020 prior to regional and national shutdown. All donors with a recent travel history to China, Hong Kong, Macau, Iran, Italy, and South Korea were deferred for 28 days. Donors diagnosed or suspected to have COVID-19 or had contact with a COVID-19 positive patient were also deferred for 28 days despite the absence of any data or evidence as of yet that SARS-CoV-2 can be transmitted through blood products [19] .

Several measures were adopted by all blood donation centers and blood drives to prevent transmission of SARS-CoV-2. Measures included temperature screening for all donors and staff before entry into the donation centers, social distancing (>6 feet) when possible, disinfecting machines and surfaces between donations, having donors and staff wear face masks, use of hand sanitizer before and during the donation process, and increased spacing between beds. These preventative practices echoed the Centers of Disease Control (CDC) guidelines and were similarly implemented in other blood donation centers [20] [21] [22] [23] .

As these policies were put into place, blood donations began to decrease as the COVID-19 pandemic grew and blood drive cancellation increased. Regionally, one of the hospitals affected was University of Washington Medical Center, which reported a blood supply shortfall as early as February 29, 2020 [24] . Nationally blood collections dropped and in a press release by the American Red Cross on March 17, 2020, approximately 2,700 Red Cross blood drives were canceled across the country resulting in 86,000 fewer donations. Evidently, more than 80 percent of their usual blood supply comes from these blood drives [25] . Of note, as per the American Association of Blood Banks (AABB), 33,000 units of blood are needed daily to meet patient need prior to the pandemic [26].

As a result, hospitals needed to develop strategies to adapt to these blood supply shortages. Mitigation strategies that were proposed included additional criteria for transfusion orders review with more stringent guidelines. Splitting platelet units into two doses each were also considered to minimize platelet shortage. Hospitals increasingly adopted these measures over the course of a few weeks starting in March 2020 [27].

On April 2, 2020, the FDA issued new blood donation guidance to address the need for blood and blood components. They no longer required collections to be discarded due to errors in J o u r n a l P r e -p r o o f vital signs or donation intervals and added a 72 hour window to allow a donor to respond to questions about eligibility and component suitability [28] . The FDA changed deferral guidelines and a previous guidance that deferred many donors for up to 12 months due to various reasons was revised to a deferral of 3 months (Table 1 ) [29] . In addition, donors who were previously permanently deferred between 1980-1986 due to spending more than 3 months in specified European countries were allowed to be reconsidered for donation. Exceptions and alternatives were also issued under 21 CFR 640.120(b) to address blood and blood component shortages [30] .

Concurrently, the CDC and Centers for Medicare and Medicaid Services (CMS) recommended rescheduling elective surgeries as needed and shifting elective urgent inpatient surgical procedures to outpatient settings when feasible. The American College of Surgeons similarly recommended the same guidelines [31] . They stated surgeries should be reviewed with "a plan to minimize, postpone, or cancel electively scheduled operations, endoscopies, or other invasive procedures" [32] . These policies were initiated by hospitals like University of Washington Medical Center where elective surgeries and procedures were postponed starting March 7, 2020. During that time, blood usage and blood demand reached parity at Washington Medical Center [24] . This decrease in elective surgery was echoed in many hospitals with one report citing a 71.7 % decrease in surgical volume [33] .

Nationally, elective surgery cancellation and blood mitigation strategies became ubiquitous as seen by the AABB survey. The week of March 23, 2020 a majority of hospitals reported they were no longer performing elective surgeries with only 10.6% of hospitals still conducting elective surgeries [34] . Blood usage mitigation techniques as mentioned above became more prevalent [27] . In fact, blood wastage increased the following week, March 30 th , J o u r n a l P r e -p r o o f with 25% of hospitals reporting increased blood wastage due to cancellation of elective surgeries and non-urgent medical procedures [35] . Wastage peaked the week of May 4 at 54% and the subsequent week, May 11, decreased to 52% as many hospitals started to resume elective procedures ( Figure 1 ) [36, 37] .

Blood transfusion is considered one of the most common hospital procedures performed in the U.S. The safety of blood products and the appropriateness of transfusion are significant and timely issues. Over the last three decades, studies have shown that transfusion of one red blood cell (RBC) unit increases wound complications by 4%, hospital length of stay (LOS) by 1.5 days, and mortality by 0.9% [38] [39] [40] . In non-bleeding patients, restricting blood transfusions by using a hemoglobin (Hgb) trigger of <7 g/dL significantly reduces cardiac events, rebleeding, bacterial infections, and total mortality [41] . Other blood components carry similar risks. Plasma is frequently misused and its benefits are overestimated particularly in nonbleeding patients. In a retrospective cohort study, Warner et al. [42] found that prophylactic administration of plasma in the critically ill was not associated with improved clinical outcomes.

Similar studies on prophylactic pre-procedure platelet transfusion showed an increase in risk of thrombosis and mortality [43] .

Patient Blood Management (PBM) is a multidisciplinary, evidence based strategy in which the need for blood products is managed in order to provide better patient outcomes and appropriate stewardship of a limited resource while reducing health care costs ( Table 2 ). The J o u r n a l P r e -p r o o f primary goal of PBM program is to ensure optimal decision support using evidence based guidelines and transfusing the most appropriate blood product(s) with a minimum dose required for the clinical situation [44] . In addition, pharmaceutical products such as desmopressin (DDAVP) and antifibrinolytics (such as Amicar or Tranexamic acid) have been shown to reduce bleeding [45] [46] [47] [48] . Prothrombin complex concentrates and Vitamin K may also be effective in warfarin reversal and correcting INR [49] [50] [51] . Iron supplements, oral or intravenous preparations, and Erythropoiesis-Stimulating Agents (ESA) are proven to be useful in repleting iron stores and thus increasing hemoglobin levels [52] . PBM and bloodless medicine programs is now a priority throughout national and international health-systems ( Figure 2 ) [53] . Hospitals and academic medical centers across the nation are beginning to develop bloodless medicine and PBM programs in response to the favorable evidence.

During the 2020 COVID-19 pandemic, blood supply shortages were observed worldwide including the U.S. The major blood suppliers and hospitals across the country, issued emergency pleas for donations and reports significant numbers of blood drives were canceled due to school and workplace closures. This resulted in thousands of fewer blood donations typically collected [19] . In Beijing, China during the 2003 SARS epidemic, blood products shortages necessitated importation of blood products from other Chinese provinces to supply needs for clinical use in patients [54, 55] . Similarly, the COVID-19 pandemic has had a major ripple effect on the number of eligible blood donors, blood supply, and on blood safety. Therefore, PBM strategies are imperative in order to manage shortages during natural disaster or disease pandemics as well as long term socioeconomic effects following these crises.

Implementation of the most recent evidenced supported transfusion guidelines and eliminating unnecessary transfusions are considered the main goals of PBM programs during major disasters.

Some effective strategies are as follows:

• Evaluation of appropriateness of transfusion orders and further discussion with clinical team if needed.

• Use of other pharmaceutical products such as Desmopressin, Antifibrinolytics, Vitamin K, Prothrombin Complex Concentrates, or intravenous Iron if appropriate.

• Blood sparing strategies during surgery such as implementation of normovolemic or hemodilution measures or usage of cell salvage.

Although the demand for blood products during the COVID-19 pandemic has decreased due to postponement of elective surgeries, hospitals must have an emergency blood management plan. This plan should be in place and ready to be implemented during and following any natural crisis in order to maintain sustainability of a safe blood supply. As hospitals resume elective surgery and see increases in non-COVID-19 admissions, long-term shortages beyond the pandemic peak persist. At this time, blood collection centers and donors are still required to avoid large gatherings and follow all safety measures. Thus, a significant blood supply shortage may be present beyond the pandemic peak. In addition, due to the prolonged incubation period (up to 14 days) of SARS-CoV-2 and the potential of asymptomatic carriers, recruitment of blood donors as well as maintaining safety in the blood collection process remains a major concern.

J o u r n a l P r e -p r o o f

Being prepared to face a pandemic ensures that blood products are available to those patients requiring transfusion support and a robust plan helps to protect the safety and health of the transfusion service professionals needed to perform testing and prepare blood products [56] .

The effects of any pandemic on transfusion service and blood bank operations are twofold, the work force and the blood supply.

While many employees were encouraged or required to work remotely during the COVID-19 pandemic, this is not an option for laboratory professionals working in an academic medical center transfusion service and blood bank. To provide necessary transfusion support and to prepare and modify blood products, blood bank employees must be physically present in the laboratory at all times. Thus, for employees' safety and to prevent the spread of infection, The second concern that transfusion services and blood banks may experience during a pandemic is the blood products supply. Blood collection mainly depends on volunteer blood donors at collection centers. During such a crisis blood donation can be greatly reduced as a result of donors becoming infected, unable to donate, or avoid public gatherings [57] . A number of conservation options should be considered by the transfusion service in order to conserve a rapidly dwindling blood supply along with additional measures promoted by a PBM program, when available.

• The blood type of trauma patients should be determined as rapidly as possible so that transfusion can be performed using type specific RBC thereby conserving the supply of group "O" RBC, a universal donor type. Group "O" Negative RBC should be reserved for women of childbearing age (<50 years) and female children. All other group "O" individuals should receive group "O" Positive RBC.

• If platelet availability is constrained, units can be split into two doses. At our facility we have found that a half unit of platelets is sufficient to provide clinical benefit to most patients. However, based on the patient's clinical condition, a full dose can be transfused if required.

• Due to decreased blood utilization as a result of elective procedures withholding, reducing standing orders and managing blood product standing orders with the blood supplier is essential to minimize waste, particularly in multisite hospital systems with transfusion services located at each hospital. Transferring RBC to the highest transfusion volume facility in the health care system could be an option as well to reduce wastage.

• Inventory levels of reagents and supplies must be closely monitored. The transfusion service must work closely with the supply chain to ensure that critical reagents and supplies are available throughout the pandemic to perform critical testing. This may involve placing orders to bring levels to a level sufficient to perform testing for 3 months or more if availability or delivery could potentially be a problem.

• To assist the blood supplier, facilities could host additional blood drives either at the facility itself (if there is sufficient room to ensure adequate social distancing) or supporting drives in a larger venue (such as a mall closed due to the pandemic or a government building not currently or minimally occupied).

• If the hospital blood bank is FDA registered or licensed, the collection of convalescent plasma could be undertaken to provide a possible course of treatment either alone or in combination with other treatments to infected patients [58] .

While blood conservation measures may be necessary, there likely will be a decrease in demand for RBC resulting from canceling elective surgical procedures. In the COVID-19 pandemic a reduction in blood orders from our blood supplier reduced spending at our facility by approximately 50%. Blood bank serologic testing was reduced by approximately 30% during the same time period but without the associated decrease in budget due to the advanced purchase of reagents and supplies. Close monitoring of testing volumes, blood product purchases and waste is important to determine how the pandemic will affect cost projections.

Unlike other subspecialties in pathology and laboratory medicine, transfusion medicine/blood banking is almost exclusively focused on therapeutics, including hands on treatment of patients. Thus it is understandable that physicians, nurses and medical technologists in this area of medicine have been focused on possible treatment approaches for COVID-19. In the absence of effective and safe anti-viral treatments, the strategy of transfusing convalescent plasma has long attracted interest and been used in treatment of infectious disease, most recently in viral diseases [59] . The interest is due to the abundant evidence that humoral immunity plays a role in resolution of viral infection and prevention of reinfection after primary infection or vaccination. Convalescent plasma has a long history but almost no quality evidence for its efficacy and safety, as its use has often been reserved for last ditch efforts in desperately ill patients. In addition, much of the history of its use antedates the recognition that randomized trials are needed for ultimate proof of efficacy and safety due to the highly variable course of many illnesses, including COVID-19 [60] .

In the current pandemic, early case reports of convalescent plasma usage reported that some patients who were seriously ill, requiring ICU care and mechanical ventilation [61] , cleared virus more rapidly than expected and made sufficient recovery and shorter LOS. Thousands of units of plasma, almost all untested for anti-viral neutralizing titers have been transfused in the USA employing FDA approved emergency investigational new drug (IND) and expanded access protocols [62] . Many small randomized trials and a few larger multi-center trials are underway a few months into the epidemic in the USA. These include some trials in patients with critical illness, employing primary endpoints for efficacy such as ability to be weaned from mechanical ventilation, discharge from hospital and survival. Other trials target prevention of infection in J o u r n a l P r e -p r o o f exposed individuals, or prevention of hospitalization in newly SARS-CoV-2 RNA positive individuals with mild or moderate symptoms. In most cases, given the uncertainty of whether antibody is protective, no specific titer or neutralizing titer of antibody in the plasma is specified.

In other trials, high titers of antibody are required (e.g., reactive at >1:320). Donors must meet standard FDA and state safety requirements for blood donation and be either RNA negative or >28 days past clinical recovery in order to donate [63] . Donation can be by manual plasmapheresis or machine apheresis, with the former considerably less efficient but less costly.

There are many unresolved issues concerning convalescent plasma efficacy and safety. Some examples include [59] does antibody clearance of virus lead to clinical improvement in moderately to severely ill patients?, [60] does antibody prevent clinical deterioration in recently infected, asymptomatic or mildly symptomatic patients?, and [61] are there mid-to longer term consequences of transfusing allogeneic plasma? Many statements have been made that allogeneic plasma transfusion is a common therapy with only rare acute complications (acute lung injury, volume overload, hemolysis, anaphylaxis, etc.). However, recent observational literature in critically ill patients demonstrate that allogeneic plasma transfusion is associated with nosocomial bacterial infection [64] , organ failure and thrombosis [65] . The role of transfusing ABO "compatible plasma," an accepted practice, in worsening the risk of bleeding [66] , infection/sepsis [67] , organ failure [67] and mortality [66] is not proven, but transfusion of ABO compatible but not identical plasma is likely not immunologically neutral. Immune complexes between antibody and soluble antigen form after transfusion and, at least in model systems, can activate monocytes, interfere with platelet and coagulation factor function, and may injure endothelial cells [68] .

J o u r n a l P r e -p r o o f A likely more efficacious and safer product than convalescent plasma being considered for use in COVID-19 disease and its prevention is hyperimmune IgG. IVIgG made from multiple donors with detectable titers of anti-SARS-CoV-2 antibody would be expected to more potent and carry fewer risks than convalescent allogeneic plasma that has not been processed [69] .

However, it will be many months before such products are routinely available much less proven effective and safe in patients. One clear cut benefit of IVIgG is a reduced risk of some adverse immune effects (acute lung injury, hemolysis, organ failure) because no single donor is heavily represented. Infectious disease transmission, while uncommon after plasma that has been tested for HIV, hepatitis C, etc. is in general, not a risk with use of IVIgG preparations. Both convalescent plasma and hyperimmune IgG may carry risks of antibody enhancement of viral infection [70] .

Finally, while not a blood product, humanized monoclonals to proteins and glycoproteins that are necessary for viral entry and replication hold some promise as preventive and therapeutic strategies in COVID-19.

Steps Taken to Protect Blood Supply

In general, blood donors must be healthy on the day of donation and meet existing FDA donor screening measures. Typically, these measures should prevent individuals with any respiratory symptoms or infection from donation. Donors are also instructed to contact the blood collection center if any signs or symptoms developed within the next few days of donation. The collected blood or blood components will then be discarded and any distributed products will be recalled.

Nevertheless, to date no transfusion-transmitted COVID-19 cases have been reported. However, specific IgG and IgM against SARS-CoV-2 by ELISA were negative, indicating the possibility of infection in the early stage. The author concluded that due to the asymptomatic COVID-19 cases, screening donors for SARS-CoV-2 will be critical to ensure blood safety.

Hence, to date there are no FDA requirements in place to screen blood donors or test blood components for COVID-19. Individuals with COVID-19 infection do not meet the blood donation guidelines.

J o u r n a l P r e -p r o o f 

A new coronavirus associated with human respiratory disease in China

Coronavirus Infections-More Than Just the Common Cold

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review

Clinical Characteristics of Coronavirus Disease 2019 in China

Cautious handling of urine from moderate to severe COVID-19 patients

Human coronavirus circulation in the United States 2014-2017

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity

COVID-19 diagnosis and management: a comprehensive review

The role of interleukin-6 in monitoring severe case of coronavirus disease 2019

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Treatment options for COVID-19: The reality and challenges

What to know about the Coronavirus and Blood Donation

COVID-19 and the Blood Supply

Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State

American Red Cross Faces Severe Blood Shortage As Coronavirus Outbreak Threatens Availability of Nation's Supply

Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research

Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic

Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency

Healthcare Facilities: Preparing for Community Transmission

COVID-19: Recommendations for Management of Elective Surgical Procedures

Emerging Practice Patterns in Vascular Surgery During the COVID-19 Pandemic

AABB Survey COVID-19 Impact on Care of Patients Requiring Transfusion: Week 1 Snapshot

AABB Survey COVID-19 Impact on Care of Patients Requiring Transfusion: Week 2 Snapshot

Surgical outcomes and transfusion of minimal amounts of blood in the operating room

Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients

update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines

Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial

Prophylactic Plasma Transfusion Is Not Associated With Decreased Red Blood Cell Requirements in Critically Ill Patients

Prophylactic Preprocedure Platelet Transfusion Is Associated With Increased Risk of Thrombosis and Mortality

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs

Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding

Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery

Tranexamic acid: a review of its use in surgery and other indications

Desmopressin acetate (DDAVP) to prevent bleeding in percutaneous kidney biopsy: a systematic review

Four-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding: A Post Hoc Analysis of Two Randomized Controlled Trials

Effect of vitamin K administration on rate of warfarin reversal

EFFICACY AND SAFETY OF 4F-PCC VS. FFP FOR WARFARIN REVERSAL IN EMERGENT SURGERY/INVASIVE PROCEDURE

Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients: Results From a Systematic Review and Meta-analysis

Blood-management programs: a clinical and administrative model with program implementation strategies

Blood transfusion during the COVID-19 outbreak

The active role of a blood center in outpacing the transfusion transmission of COVID-19

AABB Interorganizational Task Force on Pandemic Influenza and the Blood Supply

Maintaining a Safe and Adequate Blood Supply during Pandemic Influenza, in Guidelines for Blood Transfusion Services. World Health Organization (WHO)

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Deployment of convalescent plasma for the prevention and treatment of COVID-19

COVID-19 Convalescent Plasma: Now Is the Time for Better Science

Convalescent plasma for patients with COVID-19

Plasma transfusion is associated with postoperative infectious complications following esophageal resection surgery: a retrospective cohort study

The incidence of venous thromboembolism in children following colorectal resection for inflammatory bowel disease: A multi-center study

An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients

Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients

Is It Time to Reconsider the Concepts of "Universal Donor" and "ABO Compatible" Transfusions?

Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Clin Immunol

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations

For female donors who would have been deferred for having sex with a man who had sex with another man For those with recent tattoos and piercings For those who have traveled to malaria-endemic areas (and are residents of malaria non-endemic countries): the agency is changing the recommended deferral period from 12 months to 3 months. In addition, the guidance provides notice of an alternate procedure that permits the collection of blood and blood components from such donors without a deferral period, provided the blood components are pathogen-reduced using an FDAapproved pathogen reduction device.For those who spent time in certain European countries or on military bases in Europe who were previously considered to have been exposed to a potential risk of transmission of Creutzfeldt-Jakob Disease or Variant Creutzfeldt-Jakob Disease, the agency is eliminating the recommended deferrals and is recommending allowing reentry of these donors.From indefinite deferral to no deferral *Policy of various blood centers [20] [21] [22] [23]